Printer Friendly

Positive Association between EDN1 rs5370 (Lys198Asn) Polymorphism and Large Artery Stroke in a Ukrainian Population.

1. Introduction

As it is well known, endothelial dysfunction plays an important role in the development of common cardiovascular diseases and their complications [1]. One of the main pathogenetic pathways of endothelial dysfunction development is an increased formation and biological activity of the powerful vasoconstrictor and proinflammatory peptide endothelin (ET-1) [2], which mediates own effects via two pharmacologically distinguishable receptor subtypes, endothelin A (ETA) and endothelin B (ETB) receptors, respectively [3]. There are several lines of evidence indicating that the ET-1-induced endothelial dysfunction is realized through decreasing production and increasing degradation of NO, through enhancement of Von Willebrand factor and reactive oxygen species formation, and also through the activation of proinflammatory metabolic pathways in the endotheliocytes [4].

In recent years, a wide range of case-control studies to test the association between various single nucleotide polymorphisms (SNPs) of the ET-1 (EDN1) and its receptor (EDNRA and EDNRB) genes and development of arterial hypertension (AH) [5, 6], pulmonary hypertension [7], myocardial infarction [8], diabetic retinopathy [9] and nephropathy [10], metabolic syndrome [11], and hemorrhagic stroke [12] have been carried out. There are several works that concern the investigation of the effect of EDN1, EDNRA, and EDNRB genetic polymorphisms on ischemic stroke (IS) development. Zhang and Sui showed that rs5370-T allele (EDN1 gene) increased the IS incidence risk in Northern Han men, whereas the rs5335-CC genotype (EDNRA gene) had a protective effect in the same population [13]. Yamaguchi et al. revealed a significant association between EDN1 rs5370 polymorphism and high risk for IS only among Japanese women [14], whereas Aslan et al. and Gormley et al. did not find any relation between the mentioned SNP and stroke morbidity among the Turkish [15] and English [16] population, respectively. Thus, the data obtained in different populations are contradictory, which requires further study about the role of polymorphic variants of the endothelin family genes in the IS development.

The aim of the present case-control study was to investigate the possible association between EDN1 rs5370 and EDNRA rs5335 polymorphisms and large artery stroke (LAS) in representatives of the Ukrainian population.

2. Materials and Methods

2.1. Study Population. Venous blood of 200 unrelated Caucasians (Ukrainians) with LAS (89 females and 111 males; mean age [[+ or -]SD] 66.7 [+ or -] 10.1) and 200 control subjects (75 females and 125 males; mean age 68.1 [+ or -] 13.9) was used for the study. Each stroke patient had been under dispensary observation in the 5th Sumy Clinical Hospital since April 2009 to December 2017. Computed tomography and (or) magnetic resonance imaging investigations of the head as well as electrocardiographic, biochemical, and coagulation tests and carotid ultrasonography were used for final LAS diagnosis establishment. The pathogenic variant of IS was determined according to the TOAST criteria [17]. Individuals with cardioembolic, lacunar, and hemorrhagic strokes, traumatic brain injury, and brain tumors were excluded. The clinical characteristics of LAS patients included systolic, diastolic, pulse and mean arterial blood pressure (BP), body mass index (BMI), lipid profile parameters, and coagulogram indices.

Only participants without the history of IS or other acute cerebrovascular pathologies, myocardial infarction, and other atherosclerosis complications were enrolled to the control group. Subjects of the comparison groups were divided into subgroups defined by sex and the presence or absence of AH (systolic BP > 140mmHg, diastolic BP > 90mmHg, or both). The study protocol complied with the Declaration of Helsinki and was approved by the Ethic Committee of the Medical Institute of Sumy State University (number 2/02.17.09). An appropriate written informed consent was obtained from all individuals.

2.2. Genotyping of SNPs. Genomic DNA was isolated from peripheral leukocytes using GeneJET Whole Blood Genomic DNA Purification Mini Kit (Thermo Fisher Scientific, USA). Polymerase chain reaction-restriction fragment length polymorphism analysis (PCR-RFLP) was used for genotyping EDN1 rs5370 and EDNRA rs5335 SNPs. The reaction mixture for PCR (total volume 25 [micro]L) included 2 mM MgS[O.sub.4], 0.2 mM dNTPs (Thermo Fisher Scientific, USA), 5 [micro]L 5 x PCR buffer, 1U Taq DNA polymerase (Thermo Fisher Scientific, USA), and 75-100 ng DNA. The nucleotide structure of the primers and PCR conditions, which were used for each polymorphism investigation, are shown in Table 1. PCR was carried out in Thermocycler GeneAmp PCR System 2700 (Thermo Fisher Scientific, USA).

2U of Cac81 (Thermo Fisher Scientific, USA) was used for restriction analysis of EDN1 rs5370 polymorphism (incubation at 37[degrees]C for 17 h). The presence of guanine at the 5665th position of the EDN1 gene led to the cleavage of the amplicon (262 bp) by Cac81 into two parts of 189 and 73 bp. In the case of guanine to thymine replacement, we had only one 262 bp fragment due to the loss of the Cac81 catalytic site (Figure 1). Restriction analysis of EDNRA rs5335 SNP required using 3 U of NmuCI (Tsp45I) (Thermo Fisher Scientific, USA) (incubation at 37[degrees]C for 19 h). The presence of cytosine at the 70th position of the EDNRA 3,-untranslated region (3;-UTR) allowed NmuCI to cut the primary amplicon (174 bp) into two fragments of 116 and 58 bp. Cytosine to guanine substitution resulted in preventing the restriction and preservation of the original 174 bp fragment (Figure 2). Horizontal electrophoresis (10 V/cm) in 2.5% agarose gel (10 mg/mL ethidium bromide) with subsequent ultraviolet visualization was used for restriction fragment detection.

2.3. Statistical Analysis. The Statistical Package for Social Science software (SPSS, version 17.0, Chicago, IL, USA) was used for most statistical analyses. Continuous variables are presented as the mean [+ or -] SD (checking the normality of distribution was performed using Shapiro-Wilk test); categorical variables are presented as absolute number and percentage value. Two-tailed Student's t-test and ANOVA with subsequent Bonferroni post hoc test were used for comparison of the mean values between two or more different patient groups. In order to control type 1 error, multiple adjustment using false discovery rate (FDR) method was performed. Statistical power analysis was done using Quanto. Hardy-Weinberg equilibrium testing was carried out using Online Encyclopedia for Genetic Epidemiology Studies (http://www.oege.org/software/hardy-weinberg.html). Chi square ([chi square]) test was used to compare the frequency of EDN1 rs5370 and EDNRA rs5335 alleles and genotypes as well as other categorical variables between the control and case groups. An odds ratio (OR) and 95% confidence interval (CI) were obtained from logistic regression for dominant, recessive, and additive models of inheritance. Multivariable logistic regression was used to exclude the effect of other atherosclerosis risk factors including sex, age, BMI, AH, type 2 diabetes mellitus (T2DM), and smoking status. All statistical tests were based on a two-tailed probability; a value of P < 0.05 was considered as significant.

2.4. Prediction Analysis. In order to uncover the functional effects of EDN1 rs5370 and EDNRA rs5335 polymorphic sites, web available consensus classifiers PredictSNP2 [18] and SNPinfo were used [19]. Herewith to predict the effect of rs5370 SNP of the EDN1 5 exon on protein function PredictSNP was used [20]. We also used SpliceAid2 tool to check if SNP 5370 is located in splicing regulatory sequence [21]. Online miRDB resource [22] was used for microRNA target prediction in the framework of the functional analysis of rs5335 SNP of EDNRA 3'-UTR.

3. Results

The general characteristics of the study groups are summarized in Table 2. Their detailed description was presented in our previous article [23].

The distribution of EDN1 rs5370 and EDNRA rs5335 alleles and genotypes in comparison groups is shown in Table 3. Obtained genotype frequencies for each SNP did not significantly deviate from Hardy-Weinberg equilibrium expectations ([P.sub.HWE] > 0.05). The frequency of EDN1 rs5370 genotypes and alleles in LAS patients significantly differed from the control group (P = 0.006 and P = 0.002, resp.), while the distribution of EDNRA rs5335 genotypes and alleles was similar between case and control individuals (P = 0.391 and P = 0.521, resp.). Statistical power analysis indicated that the rs5370 locus had strong power (0.689--for dominant model; 0.956--for recessive model; and 0.991--for additive model). At the same time, rs5335 SNP had poor power (0.252--for dominant model; 0.059--for recessive model; and 0.654--for additive model).

The results of two investigated SNP genotypes' association with LAS are presented in Table 4. Significant association between EDN1 rs5370 and stroke was revealed under dominant ([P.sub.c] = 0.012; [OR.sub.c] = 1.657, 95% CI = 1.115-2.462), recessive ([P.sub.c] = 0.007; [OR.sub.c] = 2.839, 95% CI = 1.331-6.057), and additive ([P.sub.c] = 0.003; [OR.sub.c] = 3.291, 95% CI = 1.512-7.165--for TT genotype) models of inheritance. After adjusting for covariates of age, sex, BMI, AH, T2DM, and smoking status, genotypic association of rs5370 SNP remained under dominant ([P.sub.a] = 0.020; [OR.sub.a] = 1.601, 95% CI= 1.066-2.403), recessive ([P.sub.a] = 0.003; [OR.sub.a] = 3.251, 95% CI= 1.492-7.084), and additive ([P.sub.a] = 0.002; [OR.sub.a] = 3.637, 95% CI= 1.6398.073--for TT genotype) models. Logistic regression analysis for EDNRA rs5335 did not show any significant link with LAS development neither before nor after adjustment for atherosclerosis risk factors (P > 0.05).

The analysis of rs5370 and rs5335 genotypic association with LAS risk in female and male subjects is presented in Table 5. In women, significant difference for rs5370 locus was revealed in the crude dominant ([P.sub.c] = 0.021; [OR.sub.c] = 2.090, 95% CI = 1.119-3.903) and additive ([P.sub.c] = 0.034; [OR.sub.c] = 2.008, 95% CI = 1.055-3.823--for GT genotype) models, as well as in adjusted dominant ([P.sub.a] = 0.014; [OR.sub.a] = 2.437, 95% CI = 1.202-4.940) and additive ([P.sub.a] = 0.042; [OR.sub.a] = 2.135, 95% CI = 11.079-4.393--for GT genotype; [P.sub.a] = 0.018; [OR.sub.a] = 5634, 95% CI= 1.157-27.436--for TT genotype) models. EDNRA rs5335 SNP was not associated with stroke development in the female subgroup (P > 0.05). In male subjects, association of rs5370-TT genotype was revealed regardless of adjustment under recessive ([P.sub.c] = 0.007, [P.sub.a] = 0.007; [OR.sub.a] = 3.512, 95% CI = 1.401-8.806) and additive models ([P.sub.c] = 0.008, [P.sub.a] = 0009; [OR.sub.a] = 3.535, 95% CI = 1.377-9.076). The significant link between rs5335 polymorphism and LAS development in the mentioned subgroup was absent (P > 0.05).

Due to influential role of the endothelin pathway in hypertension development, we also investigated the association between EDN1 and EDNRA gene polymorphisms and ischemic stroke development in patients with and without AH (Table 6). In nonhypertensive subjects, both SNPs were not associated with LAS either before or after adjustment for age, sex, BMI, T2DM, and smoking (P > 0.05). In the hypertensive cohort, the minor T allele for the rs5370 locus was found to be significantly more prevalent in stroke patients. Before adjusting for covariates, positive association was revealed under dominant ([P.sub.c] = 0.045; [OR.sub.c] = 1649, 95% CI= 1.011-2.689), recessive ([P.sub.c] = 0.024; [OR.sub.c] = 3.220, 95% CI= 1.164-8.903), and additive ([P.sub.c] = 0.013; [OR.sub.c] = 3.744, 95% CI= 1.322-10.607--for TT genotype) models. After adjusting for the covariates, a significant link between EDN1 rs5370 and LAS remained under dominant ([P.sub.a] = 0.036; [OR.sub.a] = 1711, 95% CI = 1.035-2.829), recessive ([P.sub.a] = 0008; [OR.sub.a] = 4102, 95% CI = 1.448-11.617), and additive ([P.sub.a] = 0004; [OR.sub.a] = 4743, 95% CI= 11.633-13.776--for TT genotype) models.

Table 7 indicates the clinical characteristics of LAS patients stratified by EDN1 rs5370 genotypes. Using the ANOVA test, significant difference was found for diastolic (GG--93.4 [+ or -] 149 mmHg, GT--99.3 [+ or -] 16.2 mmHg, TT--91.7 [+ or -] 13.3 mmHg; P = 0034) BP. Nevertheless, Bonferroni post hoc test revealed no significant difference between patients with different genotypes (P = 0103 for GG versus GT; P = 0087 for GT versus TT). Moreover, FDR multiple adjustment revealed that none of the parameters are associated with rs5370 genotypes. No link between EDNRA rs5335 genotypes and BMI, BP indices, coagulogram parameters, fasting glucose, and blood plasma lipid profile in stroke patients was found (Table 8).

The bioinformatical analysis of EDN1 rs5370 by the SNPinfo tool showed that the mentioned polymorphic locus might be located in splicing regulatory sequences recognized by exonic splicing enhancers or exonic splicing silencers (score--2.56). SpliceAId2 tool demonstrated that rs5370 lies between recognized sites for SFRS9 and hnRNP H1 splicing factors, but this SNP has no influence on their structure. Finally, prediction analysis by PredictSNP and PredictSNP2 allowed classifying EDN1 rs5370 (Lys198Asn mutation) as neutral (PredictSNP--neutral with 83% expected accuracy (EA); MAPP--neutral with 68% EA; PhD-SNP--neutral with 78% EA; PolyPhen1--neutral with 67% EA; PolyPhen2--neutral with 61% EA; SIFT--neutral with 67% EA; SNAP--neutral with 50% EA; PredictSNP2--neutral with 89% EA; CADD--neutral with 90%; DANN--neutral with 73% EA; FATHMM--neutral with 84% EA; and FunSeq2--deleterious with 62% EA).

Prediction analysis of EDNRA rs5335 by the SNPinfo tool demonstrated that this SNP is possibly located in hsa-miR-27a-3p and hsa-miR-27b-3p binding sites (score--153.0). Analysis using miRDB confirmed that the EDNRA gene is in the list of mentioned miRNA targets (target score--50). However, PredictSNP2 results classified rs5335 mutation as neutral (PredictSNP2--neutral with 88% EA; CADD--neutral with 86%; DANN--neutral with 79% EA; FATHMM--neutral with 93% EA; FunSeq2--neutral with 62% EA; and GWAWA--deleterious with 64% EA).

4. Discussion

The essence of rs5370 polymorphism is the replacement of guanine by thymine at the 5665th position (5 exon) of the EDN1 gene, which in turn leads to replacement of lysine by asparagine in the 198th position of the preproendothelin-1 molecule. Several studies have shown that endothelin-1 blood plasma concentration in T (Asn) allele carriers is higher than in subjects with GG (Lys/Lys) genotype [24, 25]. Considering the localization of this SNP, it can be assumed that its functional effect is due to the effect on the quality or speed of preprodendothelin-1 posttranslational modification. However, Tanaka et al. showed that the amount of ET-1 and big ET-1 in the supernatant of Asn-type and Lys-type transfected cells was similar [26]. In addition, the plasma endothelin-1 level in patients with essential hypertension was not different in individuals with the Asn allele and Lys/Lys genotype. The conclusion that another SNP in strong LD with rs5370 may provide its clinical effects was made. Our prediction analysis of rs5370 also did not confirm the role of this polymorphic locus in preproendothelin-1 posttranslation modification. Applying bioinformatic tools did not allow highlighting the possible functional effects of the mentioned SNP. Taking together experimental and prediction data, it seems more likely that rs5370 is in strong LD with another influential SNP.

The polymorphic site rs5335 is located within the 3'-UTR of the EDNRA gene and leads to cytosine/guanine conversion at position 61,772. The functional studies of this SNP do not exist, while several clinical studies have demonstrated the association of this locus with increased risk of AH development [27, 28] and level of plasma endothelin-1 [29]. On the one hand, it can be assumed that changes in the nucleotide sequence of 3'-UTR may affect the stability of mRNA and thus a?ect the amount of the receptor protein [30]. On the other hand, this SNP may change the structure of the miRNA binding site, as it was recently shown by Ma et al. for miR-125a and rs12976445 polymorphism of the EDN1 3;-UTR [31]. In order to test these hypotheses, we used bioinformatic prediction. Our results revealed that rs5335 might change the structure of hsa-miR-27a-3p and hsa-miR-27b-3p binding sites, which are the possible regulators of EDNRA expression. Future functional analysis to confirm these results is required.

The results obtained in the present study about the link of rs5370 (EDN1 gene) and rs5335 (EDNRA gene) polymorphisms with LAS showed that in a Ukrainian population, only the rs5370 locus is associated with the development of the mentioned disease. Regardless of adjustment for other atherosclerosis risk factors, it was found that the risk of ischemic stroke development in individuals with GT and TT genotypes is higher than in GG genotype carriers. However, a similar study performed by Aslan et al. among the Turkish population did not show any correlation between EDN1 rs5370 and rs10478694 polymorphisms and ischemic cerebrovascular disease [15]. Herewith, Gormley et al. demonstrated no association between EDN1 (rs5370), EDNRA (-231G>A and +1222C>T), and EDNRB (G57S and 277L) gene polymorphisms and lacunar infarction development among English patients as well [16]. The authors of both studies have concluded that genetic variation in the endothelin pathway is not a risk factor for ischemic stroke.

The analysis performed in our work among subjects of different sexes has showed that rs5370 (EDN1), but not rs5335 (EDNRA) polymorphism, is associated with an increased risk of LAS both among women (under dominant and additive models) and men (under recessive and additive models). Such data were consistent with results obtained by Yamaguchi et al. [14], who assessed a possible association of 202 SNPs of 152 candidate genes with atherothrombotic cerebral infarction (ACI) in a large-scale Japanese cohort. Authors demonstrated that EDN1 rs5370 is related to ACI development susceptibility among women (under dominant and additive models). In the men's subgroup, the link with ischemic stroke was revealed for the EDNRA -231A>G locus (under the recessive model). At the same time, Zhang and Sui did not reveal an association between EDN1 rs5370 and EDNRA rs5335 polymorphic sites with ischemic stroke development among women of the Chinese Han population [13]. They showed that in Chinese men, the minor rs5370T allele increased the risk of stroke morbidity, while the rs5335-CC genotype, on the contrary, was associated with a low risk of ischemic stroke incident. It should also be noted that MacClellan et al. revealed the link between EDN1 (rs1800542 and rs10478723) and EDNRB (rs4885493 and rs10507875) SNPs and increased risk of ischemic stroke development in Caucasian but not in African-American women [32].

The issue of sexual difference in the endothelin system activity is one of the key topics of the cardiovascular and urinary system physiology and pathology [33]. However, the mechanism responsible for the difference in the endothelin pathway gene SNP's association with multifactorial diseases between male and female remains unclear [14, 33]. Sex differences obtained in our study can hardly be explained by the protective effect of estrogens on the vascular wall, since the studied group included mostly postmenopausal women. It can only be said that the role of individual alleles in ischemic stroke pathogenesis undoubtedly manifested in a complex set of other important risk factors. Further studies using complex analysis to draw definitive conclusion are necessary.

To date, there are number of studies about the association between endothelin system gene polymorphisms and risk of AH and pulmonary hypertension, as well as BP indices [5, 6, 11, 24, 34-36]. The present study revealed a high risk of LAS development in rs5370-T allele carriers with AH, which is inconsistent with data obtained by Yamaguchi et al. in subgroups stratified by the presence of AH in a Japanese population [14]. Our results also demonstrated a possible correlation between rs5370 polymorphism and indices of diastolic arterial blood pressure in stroke patients. Similar results were obtained for patients with preeclampsia [24], AH [34], and healthy individuals [37]. However, the association of EDN1 rs5370 locus with increased risk of AH development, as well as with different parameters of blood pressure among Australian patients with ischemic heart disease, was not found [11].

A significant limitation of our study is the relatively small number of patients enrolled into the case and control groups. Therefore, some associations between rs5370 and rs5335 SNPs and the risk of LAS development, indices of blood pressure, blood plasma lipoprotein level, and coagulation parameters might have been missed due to a small statistical power. Another limitation is the investigation of the link between SNPs and phenotype without an assessment of their effects on the EDN1 and EDNRA mRNA level and ET-1 concentration in the blood plasma. Therefore, future case-control studies involving more patients and functional studies of endothelin pathway polymorphisms effects are required.

5. Conclusion

In conclusion, this is the first evidence about the association between endothelin system genetic polymorphisms and LAS development in a Ukrainian population. Our data demonstrated that EDN1 rs5370 polymorphism is related to increased risk of LAS development regardless of other atherosclerosis risk factors. No link between EDNRA rs5335 and risk of LAS in a Ukrainian population was found. At present, a small number of case-control studies about the role of rs5370 and rs5335 SNPs in ischemic stroke development have been performed. Increasing the number of such studies with subsequent meta-analysis is necessary in order to draw a firm conclusion about the association between the mentioned polymorphisms and risk of ischemic stroke.

https://doi.org/10.1155/2018/1695782

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors' Contributions

Yevhen I. Dubovyk performed the clinical research and wrote the manuscript. Tetyana B. Oleshko performed genotyping. Viktoriia Yu. Harbuzova performed genotyping and biostatistics. Alexander V. Ataman designed the research plan and organized the study.

Acknowledgments

This study was part of the scientific project "Complex analysis of the gene polymorphisms combined effect on the vascular pathology development and consequences," supported by the Ministry of Education and Science of Ukraine.

References

[1] R. J. Widmer and A. Lerman, "Endothelial dysfunction and cardiovascular disease," Global Cardiology Science & Practice, vol. 2014, no. 3, p. 43, 2014.

[2] F. Bohm and J. Pernow, "The importance of endothelin-1 for vascular dysfunction in cardiovascular disease," Cardiovascular Research, vol. 76, no. 1, pp. 8-18, 2007.

[3] G. M. Rubanyi and M. A. Polokoff, "Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology," Pharmacological Reviews, vol. 46, no. 3, pp. 325-415, 1994.

[4] M. Iglarz and M. Clozel, "Mechanisms of ET-1-induced endothelial dysfunction," Journal of Cardiovascular Pharmacology, vol. 50, no. 6, pp. 621-628, 2007.

[5] S. R. Tamiozzo, O. C. Lassen, J. Herrera, P. Igarzabal, S. Tabares, and A. Sembaj, "Single nucleotide polymorphisms in genes of endothelin-1 and receptor A associated to cardiovascular in essential hypertension," Hipertension y Riesgo Vascular, vol. 34, no. 2, pp. 78-84, 2017.

[6] H. Yasuda, K. Kamide, S. Takiuchi et al., "Association of single nucleotide polymorphisms in endothelin family genes with the progression of atherosclerosis in patients with essential hypertension," Journal of Human Hypertension, vol. 21, no. 11, pp. 883-892, 2007.

[7] R. L. Benza, M. Gomberg-Maitland, T. Demarco et al., "Endothelin-1 pathway polymorphisms and outcomes in pulmonary arterial hypertension," American Journal of Respiratory and Critical Care Medicine, vol. 192, no. 11, pp. 1345-1354, 2015.

[8] M. Palacin, F. Rodriguez-Pascual, J. R. Reguero et al., "Lack of association between endothelin-1 gene variants and myocardial infarction," Journal of Atherosclerosis and Thrombosis, vol. 16, no. 4, pp. 388-395, 2009.

[9] L. Haitao, J. W. C. Louey, K. W. Choy et al., "EDN1 Lys198Asn is associated with diabetic retinopathy in type 2 diabetes," Molecular Vision, vol. 14, pp. 1698-1704, 2008.

[10] K. Kankova, A. Stejskalova, L. Pacal et al., "Genetic risk factors for diabetic nephropathy on chromosomes 6p and 7q identified by the set-association approach," Diabetologia, vol. 50, no. 5, pp. 990-999, 2007.

[11] S. Wiltshire, B. L. Powell, M. Jennens et al., "Investigating the association between K198N coding polymorphism in EDN1 and hypertension, lipoprotein levels, the metabolic syndrome and cardiovascular disease," Human Genetics, vol. 123, no. 3, pp. 307-313, 2008.

[12] D. Szpecht, J. Gadzinowski, A. Seremak-Mrozikiewicz, G. Kurzawinska, and M. Szymankiewicz, "Role of endothelial nitric oxide synthase and endothelin-1 polymorphism genes with the pathogenesis of intraventricular hemorrhage in preterm infants," Scientific Reports, vol. 7, article 42541, 2017.

[13] L. Zhang and R. Sui, "Effect of SNP polymorphisms of EDN1, EDNRA, and EDNRB gene on ischemic stroke," Cell Biochemistry and Biophysics, vol. 70, no. 1, pp. 233-239, 2014.

[14] S. Yamaguchi, Y. Yamada, N. Metoki et al., "Genetic risk for atherothrombotic cerebral infarction in individuals stratified by sex or conventional risk factors for atherosclerosis," International Journal of Molecular Medicine, vol. 18, no. 5, pp. 871-883, 2006.

[15] O. Aslan, M. Gurger, M. Atescelik et al., "Endothelin-1 Lys198Asn and rs10478694 polymorphism in ischemic stroke," Biomedical Research, vol. 28, no. 2, pp. 750-754, 2017.

[16] K. Gormley, S. Bevan, A. Hassan, and H. S. Markus, "Polymorphisms in genes of the endothelin system and cerebral small-vessel disease," Stroke, vol. 36, no. 8, pp. 1656-1660, 2005.

[17] H. P. Adams, B. H. Bendixen, L. J. Kappelle et al., "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment," Stroke, vol. 24, no. 1, pp. 35-41, 1993.

[18] J. Bendl, M. Musil, J. Stourac, J. Zendulka, J. Damborsky, and J. Brezovsky, "PredictSNP2: a unified platform for accurately evaluating SNP effects by exploiting the different characteristics of variants in distinct genomic regions," PLoS Computational Biology, vol. 12, no. 5, article e1004962, 2016.

[19] Z. Xu and J. A. Taylor, "SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies," Nucleic Acids Research, vol. 37, Supplement 2, pp. W600-W605, 2009.

[20] J. Bendl, J. Stourac, O. Salanda et al., "PredictSNP: robust and accurate consensus classifier for prediction of disease-related mutations," PLoS Computational Biology, vol. 10, no. 1, article e1003440, 2014.

[21] F. Piva, M. Giulietti, A. B. Burini, and G. Principato, "SpliceAid 2: a database of human splicing factors expression data and RNA target motifs," Human Mutation, vol. 33, no. 1, pp. 81-85, 2012.

[22] N. Wong and X. Wang, "miRDB: an online resource for microRNA target prediction and functional annotations," Nucleic Acids Research, vol. 43, no. D1, pp. D146-D152, 2015.

[23] Y. I. Dubovyk, V. Y. Harbuzova, and A. V. Ataman, "G-1639A but not C1173T VKORC1 gene polymorphism is related to ischemic stroke and its various risk factors in Ukrainian population," BioMed Research International, vol. 2016, Article ID 1298198, 10 pages, 2016.

[24] P. K. Aggarwal, V. Jain, R. Srinivasan, and V. Jha, "Maternal EDN1 G5665T polymorphism influences circulating endothelin-1 levels and plays a role in determination of preeclampsia phenotype," Journal of Hypertension, vol. 27, no. 10, pp. 2044-2050, 2009.

[25] A. E. Barden, C. E. Herbison, L. J. Beilin, C. A. Michael, B. N. Walters, and F. M. van Bockxmeer, "Association between the endothelin-1 gene Lys198Asn polymorphism blood pressure and plasma endothelin-1 levels in normal and preeclamptic pregnancy," Journal of Hypertension, vol. 19, no. 10, pp. 1775-1782, 2001.

[26] C. Tanaka, K. Kamide, S. Takiuchi, Y. Kawano, and T. Miyata, "Evaluation of the Lys198Asn and -134delA genetic polymorphisms of the endothelin-1 gene," Hypertension Research, vol. 27, no. 5, pp. 367-371, 2004.

[27] T. Rahman, M. Baker, D. H. Hall, P. J. Avery, and B. Keavney, "Common genetic variation in the type A endothelin-1 receptor is associated with ambulatory blood pressure: a family study," Journal of Human Hypertension, vol. 22, no. 4, pp. 282-288, 2008.

[28] A. V. Benjafield, K. Katyk, and B. J. Morris, "Association of EDNRA, but not WNK4 or FKBP1B, polymorphisms with essential hypertension," Clinical Genetics, vol. 64, no. 5, pp. 433-438, 2003.

[29] G. Okan, Z. Yildiz, G. Gokdemir et al., "G-231A and G+70C polymorphisms of endothelin receptor type-A gene could affect the psoriasis area and severity index score and endothelin 1 levels," Indian Journal of Dermatology, vol. 60, no. 2, p. 211,2015.

[30] A. F. Aydin, P. Vural, C. U. Oruc et al., "The evaluation of endothelin 1 (EDN1) and endothelin receptor type A (EDNRA) gene polymorphisms in Hashimoto's thyroiditis," International Immunopharmacology, vol. 21, no. 1, pp. 181-185, 2014.

[31] W. Ma, Q. Fu, Y. Zhang, and Z. Zhang, "A single-nucleotide polymorphism in 3'-untranslated region of endothelin-1 reduces risk of dementia after ischemic stroke," Medical Science Monitor, vol. 22, pp. 1368-1374, 2016.

[32] L. R. MacClellan, T. D. Howard, J. W. Cole et al., "Relation of candidate genes that encode for endothelial function to migraine and stroke: the Stroke Prevention in Young Women study," Stroke, vol. 40, no. 10, pp. e550-e557, 2009.

[33] W. Kittikulsuth, J. C. Sullivan, and D. M. Pollock, "ET-1 actions in the kidney: evidence for sex differences," British Journal of Pharmacology, vol. 168, no. 2, pp. 318-326, 2013.

[34] J. J. Jin, J. Nakura, Z. Wu et al., "Association of endothelin-1 gene variant with hypertension," Hypertension, vol. 41, no. 1, pp. 163-167, 2003.

[35] Z. Fang, M. Li, Z. Ma, and G. Tu, "Association of endothelin-1 gene polymorphisms with essential hypertension in a Chinese population," Genetics and Molecular Research, vol. 16, no. 3, pp. 1-7, 2017.

[36] S. Vadapalli, H. S. Rani, B. Sastry, and P. Nallari, "Endothelin-1 and endothelial nitric oxide polymorphisms in idiopathic pulmonary arterial hypertension," International Journal of Molecular Epidemiology and Genetics, vol. 1, no. 3, pp. 208-213, 2010.

[37] T. Rankinen, T. Church, T. Rice et al., "Effect of endothelin 1 genotype on blood pressure is dependent on physical activity or fitness levels," Hypertension, vol. 50, no. 6, pp. 1120-1125, 2007.

Yevhen I. Dubovyk (iD), (1) Tetyana B. Oleshko, (1) Viktoriia Yu. Harbuzova, (2) and Alexander V. Ataman (1)

(1) Department of Physiology, Pathophysiology and Medical Biology, Sumy State University, Sumy 40007, Ukraine

(2) Scientific Laboratory of Molecular Genetic Research, Sumy State University, Sumy 40007, Ukraine

Correspondence should be addressed to Yevhen I. Dubovyk; janitor@ukr.net

Received 27 September 2017; Revised 11 January 2018; Accepted 12 February 2018; Published 3 April 2018

Academic Editor: Matteo Giulietti

Caption: Figure 1: Results of EDN1 rs5370 polymorphism restriction analysis. M--molecular marker (bp--base pairs); lanes 3, 4, 5, and 8--GG genotype; lanes 6, 7, 10, and 11--GT genotype; lanes 1, 2, and 9--TT genotype.

Caption: Figure 2: Results of EDNRA rs5335 polymorphism restriction analysis. M--molecular marker (bp--base pairs); lanes 8 and 10--CC genotype; lanes 1, 2, 3, 4, 5, 6, and 11--CG genotype; lanes 7 and 9--GG genotype.
Table 1: PCR conditions for EDN1 rs5370 and EDNRA rs5335 genotyping.

Gene     SNP         Primer nucleotide sequence

EDN1    rs5370   F: 5'-TCTTGCTTTATTAGGTCGGAGACC-3'
                   R: 5'-TTTGAACGAGGACGCTGGTC-3'
EDNRA   rs5335    F: 5'-TAGAAGCACTCCTCGGTACTCC-3'
                  R: 5'-TCG TAGATGTTGTGGGTGGATA-3'

Gene                         Thermocycling conditions

                 D                     H                     E

EDN1    94[degrees]C (60 s)   61[degrees]C (60 s)   72[degrees]C (45 s)

EDNRA   94[degrees]C (50 s)   60[degrees]C (40 s)   72[degrees]C (60 s)

Gene    PCR amplicon
            size

EDN1       262 bp

EDNRA      174bp

Annotation: F: forward; R: reverse; D: denaturation; H: hybridization;
E: elongation; bp: base pairs.

Table 2: General characteristics of the study population.

Parameter                              Cases
                                     (n = 200)

Age, years                      66.7 [+ or -] 10.1
Sex, female/male                      89/111
Body mass index, kg/[m.sup.2]    27.9 [+ or -] 3.7
Systolic BPs, mmHg              167.9 [+ or -] 28.7
Diastolic BP, mmHg              96.0 [+ or -] 15.5
Pulse BP, mmHg                  71.9 [+ or -] 22.4
Mean BPs, mmHg                  119.9 [+ or -] 17.9
Fasting glucose, mmol/L          6.05 [+ or -] 1.5
Total cholesterol, mmol/L       4.98 [+ or -] 1.46
HDL cholesterol, mmol/L         1.01 [+ or -] 0.29
LDL cholesterol, mmol/L         3.16 [+ or -] 1.39
Triglyceride, mmol/L            1.67 [+ or -] 0.78
Current smokers, n (%)               60 (30.0)
T2DM, n (%)                          50 (25.0)
Arterial hypertension, n (%)        150 (75.0)

Parameter                            Controls           P
                                     (n = 200)

Age, years                      68.1 [+ or -] 13.9    0.261
Sex, female/male                      75/125          0.155
Body mass index, kg/[m.sup.2]    27.3 [+ or -] 4.6    0.105
Systolic BPs, mmHg              151.7 [+ or -] 22.6   <0.001
Diastolic BP, mmHg              86.5 [+ or -] 11.7    <0.001
Pulse BP, mmHg                  65.2 [+ or -] 17.2    0.002
Mean BPs, mmHg                  108.3 [+ or -] 14.0   <0.001
Fasting glucose, mmol/L          5.25 [+ or -] 0.7    <0.001
Total cholesterol, mmol/L       4.75 [+ or -] 1.52    0.124
HDL cholesterol, mmol/L         1.09 [+ or -] 0.38    0.018
LDL cholesterol, mmol/L         2.94 [+ or -] 1.17    0.087
Triglyceride, mmol/L            1.54 [+ or -] 0.66    0.073
Current smokers, n (%)               55 (27.5)        0.581
T2DM, n (%)                          19 (9.5)         <0.001
Arterial hypertension, n (%)        116 (58.0)        <0.001

Categorical variables were compared by [chi square] test, continuous
variables by t-test.

Table 3: Distributions of genotypes and alleles in case and control
groups.

Gene    SNP              LAS        Control    [P.sub.HWE]   P
                       (n = 200)   (n = 200)

                      n     %      n     %

Genotypes

                GG   94    47.0   118   59.0
                GT   80    40.0   72    36.0       --        0.006
EDN1   rs5370   TT   26    13.0   10    5.0

Alleles

                G    268   67.0   308   77.0      0.991      0.002
                T    132   33.0   92    23.0

Genotypes

                CC   53    26.5   64    32.0
                CG   114   57.0   101   50.5       --        0.391
EDNRA  rs5335   GG   33    16.5   35    17.5

Alleles

                C    220   55.0   229   57.3      0.939      0.521
                G    180   45.0   171   42.7

Table 4: Analysis of EDN1 rs5370 and EDNRA rs5335 genotypic
association with LAS.

Gene     SNP        Model       [P.sub.c]   [OR.sub.c] (95% CI)

EDN1    rs5370     Dominant       0.012     1.657 (1.115-2.462)
                  Recessive       0.007     2.839 (1.331-6.057)
                 Additive (a)     0.096     1.426 (0.938-2.168)
                                  0.003     3.291 (1.512-7.165)

EDNRA   rs5335     Dominant       0.189     1.335 (0.867-2.056)
                  Recessive       0.790     0.932 (0.553-1.570)
                   Additive       0.146     1.398 (0.890-2.196)
                                  0.634     1.156 (0.636-2.103)

Gene    [P.sub.a]   [OR.sub.a] (95% CI)

EDN1      0.020     1.601 (1.066-2.403)
          0.003     3.251 (1.492-7.084)
          0.198     1.328 (0.862-2.046)
          0.002     3.637 (1.639-8.073)

EDNRA     0.110     1.440 (0.921-2.251)
          0.767     0.922 (0.539-1.578)
          0.078     1.522 (0.954-2.429)
          0.545     1.210 (0.652-2.245)

SNP: single nucleotide polymorphism; CI: confidence interval;
[P.sub.c]: crude P value; [OR.sub.c]: crude odds ratio; [P.sub.a]: P
value adjusted for age, sex, body mass index, arterial hypertension,
type 2 diabetes mellitus, and smoking; [OR.sub.a]: adjusted odds
ratio. (a) Upper row in the additive model of inheritance--comparison
between Aa and AA genotypes; lower row--between aa and AA genotypes.

Table 5: Analysis of EDN1 rs5370 and EDNRA rs5335 genotypic
association with LAS in male and female subjects.

                 Model     [P.sub.c]   [OR.sub.c] (95% CI)

EDN1 rs5370

Female         Dominant      0.021     2.090 (1.119-3.903)
               Recessive     0.312     2.049 (0.511-8.218)
               Additive      0.034     2.008 (1.055-3.823)
                             0.149     2.852 (0.681-11.827)
Male           Dominant      0.231     1.371 (0.818-2.297)
               Recessive     0.007     3.481 (1.404-8.635)
               Additive      0.939     1.022 (0.581-1.800)
                             0.008     3.510 (1.382-8.913)

EDNRA rs5335

Female         Dominant      0.220     1.523 (0.778-2.981)
               Recessive     0.273     1.579 (0.698-3.572)
               Additive      0.352     1.398 (0.691-2.831)
                             0.159     1.953 (0.770-4.952)
Male           Dominant      0.482     1.224 (0.696-2.153)
               Recessive     0.172     0.607 (0.297-1.242)
               Additive      0.257     1.405 (0.780-2.529)
                             0.505     0.758 (0.336-1.710)

                 Model     [P.sub.a]   [OR.sub.a] (95% CI)

EDN1 rs5370

Female         Dominant      0.014     2.437 (1.202-4.940)
               Recessive     0.086     3.824 (0.828-17.667)
               Additive      0.042     2.135 (1.079-4.393)
                             0.018     5.634 (1.157-27.436)
Male           Dominant      0.236     1.375 (0.812-2.330)
               Recessive     0.007     3.512 (1.401-8.806)
               Additive      0.952     1.018 (0.571-1.815)
                             0.009     3.535 (1.377-9.076)

EDNRA rs5335

Female         Dominant      0.065     2.012 (0.956-4.230)
               Recessive     0.351     1.515 (0.633-3.629)
               Additive      0.105     1.921 (0.873-4.226)
                             0.111     2.256 (0.829-6.136)
Male           Dominant      0.514     1.210 (0.682-2.148)
               Recessive     0.217     0.631 (0.304-1.310)
               Additive      0.299     1.373 (0.755-2.494)
                             0.549     0.776 (0.339-1.777)

See Table 4; [P.sub.a]: P value adjusted for age, body mass index,
arterial hypertension, type 2 diabetes mellitus, and smoking.

Table 6: Analysis of EDN1 rs5370 and EDNRA rs5335 genotypic
association with LAS in subjects with and without arterial
hypertension.

                    Model     [P.sub.c]   [OR.sub.c] (95% CI)

EDN1 rs5370

Nonhypertensive   Dominant      0.262     1.500 (0.739-3.046)
                  Recessive     0.125     2.572 (0.770-8.593)
                  Additive      0.556     1.259 (0.584-2.714)
                                0.104     2.800 (0.810-9.680)
Hypertensive      Dominant      0.045     1.649 (1.011-2.689)
                  Recessive     0.024     3.220 (1.164-8.903)
                  Additive      0.188     1.411 (0.845-2.354)
                                0.013     3.744 (1.322-10.607)

EDNRA rs5335

Nonhypertensive   Dominant      0.170     1.793 (0.779-4.125)
                  Recessive     0.443     1.457 (0.558-3.806)
                  Additive      0.218     1.715 (0.727-4.048)
                                0.196     2.127 (0.678-6.676)
Hypertensive      Dominant      0.386     1.260 (0.747-2.126)
                  Recessive     0.325     0.730 (0.390-1.366)
                  Additive      0.214     1.420 (0.816-2.471)
                                0.788     0.970 (0.445-1.850)

                    Model     [P.sub.a]   [OR.sub.a] (95% CI)

EDN1 rs5370

Nonhypertensive   Dominant      0.201     1.624 (0.773-3.411)
                  Recessive     0.118     2.685 (0.778-9.269)
                  Additive      0.470     1.348 (0.600-3.029)
                                0.093     2.980 (0.834-10.650)
Hypertensive      Dominant      0.036     1.711 (1.035-2.829)
                  Recessive     0.008     4.102 (1.448-11.617)
                  Additive      0.212     1.400 (0.825-2.374)
                                0.004     4.743 (1.633-13.776)

EDNRA rs5335

Nonhypertensive   Dominant      0.132     1.962 (0.817-4.717)
                  Recessive     0.531     1.371 (0.512-3.672)
                  Additive      0.159     1.909 (0.776-4.698)
                                0.198     2.190 (0.664-7.221)
Hypertensive      Dominant      0.271     1.353 (0.790-2.318)
                  Recessive     0.317     0.718 (0.376-1.373)
                  Additive      0.135     1.545 (0.873-2.735)
                                0.864     0.938 (0.449-1.958)

See Table 4; [P.sub.a]: P value adjusted for age, sex, body mass
index, type 2 diabetes mellitus, and smoking.

Table 7: Characteristics of the LAS subjects stratified by EDN1 rs5370
genotype.

Parameter                            Genotype

                                    GG (n = 94)

Body mass index, kg/[m.sup.2]    28.1 [+ or -] 3.6
Systolic BP, mmHg               165.1 [+ or -] 29.3
Diastolic BP, mmHg              94.4 [+ or -] 14.9
Pulse BP, mmHg                  70.7 [+ or -] 20.2
Mean BP, mmHg                   117.9 [+ or -] 18.5
Total cholesterol, mmol/L        4.91 [+ or -] 1.4
HDL cholesterol, mmol/L         1.02 [+ or -] 0.31
LDL cholesterol, mmol/L          3.10 [+ or -] 1.3
Triglyceride, mmol/L             1.65 [+ or -] 0.8
Prothrombin time, s              9.47 [+ or -] 2.0
Thrombin time, s                16.71 [+ or -] 3.7
Fibrinogen, g/L                  4.21 [+ or -] 1.3
Fasting glucose, mmol/L          6.17 [+ or -] 1.7

Parameter                            Genotype

                                    GT (n = 80)

Body mass index, kg/[m.sup.2]    27.6 [+ or -] 3.8
Systolic BP, mmHg               171.3 [+ or -] 28.8
Diastolic BP, mmHg              99.3 [+ or -] 16.2
Pulse BP, mmHg                  71.9 [+ or -] 24.8
Mean BP, mmHg                   123.3 [+ or -] 17.8
Total cholesterol, mmol/L        5.15 [+ or -] 1.6
HDL cholesterol, mmol/L         1.01 [+ or -] 0.31
LDL cholesterol, mmol/L          3.33 [+ or -] 1.5
Triglyceride, mmol/L             1.71 [+ or -] 0.8
Prothrombin time, s              9.38 [+ or -] 2.0
Thrombin time, s                16.49 [+ or -] 3.5
Fibrinogen, g/L                  3.93 [+ or -] 1.2
Fasting glucose, mmol/L          6.06 [+ or -] 1.4

Parameter                            Genotype          P value

                                    TT (n = 26)

Body mass index, kg/[m.sup.2]    28.4 [+ or -] 3.9      0.448
Systolic BP, mmHg               167.5 [+ or -] 25.9     0.372
Diastolic BP, mmHg              91.7 [+ or -] 13.3    0.034 (a)
Pulse BP, mmHg                  75.8 [+ or -] 22.5      0.600
Mean BP, mmHg                   116.9 [+ or -] 15.2     0.099
Total cholesterol, mmol/L        4.74 [+ or -] 1.3      0.374
HDL cholesterol, mmol/L         0.96 [+ or -] 0.25      0.610
LDL cholesterol, mmol/L          2.89 [+ or -] 1.3      0.347
Triglyceride, mmol/L             1.58 [+ or -] 0.7      0.750
Prothrombin time, s              9.29 [+ or -] 2.0      0.900
Thrombin time, s                17.60 [+ or -] 4.0      0.395
Fibrinogen, g/L                  3.64 [+ or -] 1.3      0.089
Fasting glucose, mmol/L          5.59 [+ or -] 1.0      0.236

Parameter                       [P.sub.FDR]

Body mass index, kg/[m.sup.2]      0.647
Systolic BP, mmHg                  0.642
Diastolic BP, mmHg                 0.429
Pulse BP, mmHg                     0.720
Mean BP, mmHg                      0.429
Total cholesterol, mmol/L          0.641
HDL cholesterol, mmol/L            0.720
LDL cholesterol, mmol/L            0.642
Triglyceride, mmol/L               0.812
Prothrombin time, s                0.900
Thrombin time, s                   0.642
Fibrinogen, g/L                    0.429
Fasting glucose, mmol/L            0.642

n: number of cases; BP: blood pressure; HDL: high-density lipoprotein;
LDL: low-density lipoprotein; [P.sub.FDR]: P value after false
discovery rate adjustment. (a) Nonsignificant difference between GG
and GT genotypes (P = 0.103) and between TT and GT genotypes
(P = 0.087) by Bonferroni post hoc test.

Table 8: Characteristics of the LAS patients stratified by EDNRA
rs5335 genotype.

Parameter                            Genotype

                                    CC (n = 41)

Body mass index, kg/[m.sup.2]    28.7 [+ or -] 3.3
Systolic BP, mmHg               169.5 [+ or -] 26.9
Diastolic BP, mmHg              96.9 [+ or -] 12.7
Pulse BP, mmHg                  72.6 [+ or -] 21.4
Mean BP, mmHg                   121.2 [+ or -] 15.6
Total cholesterol, mmol/L        5.18 [+ or -] 1.6
HDL cholesterol, mmol/L         0.95 [+ or -] 0.31
LDL cholesterol, mmol/L          3.37 [+ or -] 1.5
Triglyceride, mmol/L             1.78 [+ or -] 0.8
Prothrombin time, s              9.81 [+ or -] 2.2
Thrombin time, s                16.63 [+ or -] 3.2
Fibrinogen, g/L                  3.95 [+ or -] 1.5
Fasting glucose, mmol/L          6.29 [+ or -] 1.8

Parameter                            Genotype

                                    CG (n = 98)

Body mass index, kg/[m.sup.2]    27.7 [+ or -] 3.8
Systolic BP, mmHg               167.3 [+ or -] 28.6
Diastolic BP, mmHg              96.7 [+ or -] 16.0
Pulse BP, mmHg                  70.6 [+ or -] 21.6
Mean BP, mmHg                   120.2 [+ or -] 18.5
Total cholesterol, mmol/L        5.01 [+ or -] 1.4
HDL cholesterol, mmol/L         1.02 [+ or -] 0.30
LDL cholesterol, mmol/L          3.18 [+ or -] 1.4
Triglyceride, mmol/L             1.66 [+ or -] 0.8
Prothrombin time, s              9.26 [+ or -] 1.9
Thrombin time, s                16.72 [+ or -] 3.6
Fibrinogen, g/L                  4.01 [+ or -] 1.2
Fasting glucose, mmol/L          5.99 [+ or -] 1.3

Parameter                            Genotype         P value

                                    GG (n = 31)

Body mass index, kg/[m.sup.2]    27.6 [+ or -] 3.6     0.251
Systolic BP, mmHg               167.3 [+ or -] 32.2    0.888
Diastolic BP, mmHg              91.9 [+ or -] 17.3     0.261
Pulse BP, mmHg                  75.3 [+ or -] 26.5     0.548
Mean BP, mmHg                   117.1 [+ or -] 19.7    0.573
Total cholesterol, mmol/L        4.64 [+ or -] 1.4     0.257
HDL cholesterol, mmol/L         1.07 [+ or -] 0.27     0.179
LDL cholesterol, mmol/L          2.83 [+ or -] 1.3     0.235
Triglyceride, mmol/L             1.54 [+ or -] 0.7     0.383
Prothrombin time, s              9.31 [+ or -] 1.9     0.252
Thrombin time, s                16.96 [+ or -] 4.3     0.914
Fibrinogen, g/L                  4.00 [+ or -] 1.3     0.878
Fasting glucose, mmol/L          5.89 [+ or -] 1.5     0.413

Parameter                       [P.sub.FDR]

Body mass index, kg/[m.sup.2]      0.566
Systolic BP, mmHg                  0.914
Diastolic BP, mmHg                 0.566
Pulse BP, mmHg                     0.745
Mean BP, mmHg                      0.745
Total cholesterol, mmol/L          0.566
HDL cholesterol, mmol/L            0.566
LDL cholesterol, mmol/L            0.566
Triglyceride, mmol/L               0.671
Prothrombin time, s                0.566
Thrombin time, s                   0.914
Fibrinogen, g/L                    0.912
Fasting glucose, mmol/L            0.671

See Table 7.
COPYRIGHT 2018 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Dubovyk, Yevhen I.; Oleshko, Tetyana B.; Harbuzova, Viktoriia Yu.; Ataman, Alexander V.
Publication:Disease Markers
Date:Jan 1, 2018
Words:7359
Previous Article:Spexin Levels Are Associated with Metabolic Syndrome Components.
Next Article:Positive Correlation of Serum N-Acetyl-[beta]-hexosaminidase with Markers of Atherosclerosis in Diabetes Type 2 Patients with Mild Symptoms of...
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |